Henlius Doses First EU Patient in Global Phase 2 Trial of HLX43 for Advanced Lung Cancer

An update from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.

Shanghai Henlius Biotech has dosed the first patient in an EU country, Spain, in an international multicentre phase 2 clinical study of HLX43, its anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer. This trial is also being conducted in Chinese Mainland, the United States, Australia and Japan, underscoring the company’s drive to globalise its oncology portfolio.

The open-label phase 2 study is designed to evaluate the efficacy and safety of HLX43 in advanced NSCLC, with dose exploration followed by a single-arm expansion focused on objective response rate as assessed by independent central review. HLX43 is in an extensive clinical programme across multiple tumour types and combinations, and the start of EU dosing marks a key step in broadening Henlius’s international clinical footprint and potentially enhancing its competitive position in the ADC and lung cancer treatment space.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing innovative biologics and antibody-drug conjugates for oncology and other serious diseases. Its pipeline includes HLX43, an anti-PD-L1 antibody-drug conjugate, along with multiple mono- and combination-therapy programmes targeting advanced and metastatic solid tumours across global markets.

Average Trading Volume: 929,524

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$38.67B

For an in-depth examination of 2696 stock, go to TipRanks’ Overview page.